FDA Approves Pancreatic Cancer Drug That Nearly Doubles Survival Time Over Chemotherapy
In a key clinical trial, patients receiving the drug achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy. The Food and Drug Administration on Wednesday approved a new treatment for advanced pancreatic cancer, which is the first to attack a genetic cause of the aggressive, highly lethal …
FDA Approves Pancreatic Cancer Drug That Nearly Doubles Survival Time Over Chemotherapy Read More »